Regeneron Pharmaceuticals (DB:RGO) - Stock Price, News & Analysis

RGO Stock Overview

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

About the company

RGO fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	2/6
Past Performance	2/6
Financial Health	5/6
Dividends	0/6

Rewards

Earnings are forecast to grow 10.93% per year

Risk Analysis

Significant insider selling over the past 3 months

Regeneron Pharmaceuticals, Inc. Competitors

Biotest

XTRA:BIO3

€1.4b

Merck KGaA

XTRA:MRK

€64.2b

Sartorius

XTRA:SRT3

€16.9b

Gilead Sciences

NasdaqGS:GILD

US$83.5b

Price History & Performance

Summary of all time highs, changes and price drops for Regeneron Pharmaceuticals
Historical stock prices
Current Share Price	US$853.60
52 Week High	US$920.00
52 Week Low	US$628.00
Beta	0.14
1 Month Change	-4.09%
3 Month Change	-2.89%
1 Year Change	18.06%
3 Year Change	110.12%
5 Year Change	179.87%
Change since IPO	1,480.74%

Recent updates

Shareholder Returns

	RGO	DE Biotechs	DE Market
7D	1.6%	-5.1%	-2.0%
1Y	18.1%	-21.1%	-0.3%

Return vs Industry: RGO exceeded the German Biotechs industry which returned -21.1% over the past year.

Return vs Market: RGO exceeded the German Market which returned -0.3% over the past year.

Price Volatility

Is RGO's price volatile compared to industry and market?
RGO volatility
RGO Average Weekly Movement	2.0%
Biotechs Industry Average Movement	5.0%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.0%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: RGO has not had significant price volatility in the past 3 months.

Volatility Over Time: RGO's weekly volatility (2%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1988	13,450	Leonard Schleifer	www.regeneron.com

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults.

Regeneron Pharmaceuticals, Inc. Fundamentals Summary

How do Regeneron Pharmaceuticals's earnings and revenue compare to its market cap?
RGO fundamental statistics
Market cap	€90.77b
Earnings (TTM)	€3.71b
Revenue (TTM)	€12.31b

24.5x

P/E Ratio

7.4x

P/S Ratio

Is RGO overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
RGO income statement (TTM)
Revenue	US$13.12b
Cost of Revenue	US$6.25b
Gross Profit	US$6.86b
Other Expenses	US$2.91b
Earnings	US$3.95b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

May 02, 2024

Earnings per share (EPS)	36.79
Gross Margin	52.32%
Net Profit Margin	30.14%
Debt/Equity Ratio	7.6%

How did RGO perform over the long term?

See historical performance and comparison

RGO Stock Overview

Rewards

Risk Analysis

Regeneron Pharmaceuticals, Inc. Competitors

XTRA:BIO3

€1.4b

XTRA:MRK

€64.2b

XTRA:SRT3

€16.9b

NasdaqGS:GILD

US$83.5b

Price History & Performance

Recent News & Updates

Regeneron Pharmaceuticals, Inc. Announces Positive Pivotal Data from the Phase 1/2 LINKER-MM1 Trial of Linvoseltamab in Patients with Heavily Pre-Treated Multiple Myeloma

Regeneron Pharmaceuticals, Inc., Annual General Meeting, Jun 14, 2024

Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) completed the acquiistion of R&D pipeline from 2seventy bio, Inc. (NasdaqGS:TSVT) for $20 million.

Regeneron Pharmaceuticals, Inc Provides Update on Biologics License Application for Odronextamab

Regeneron Pharmaceuticals, Inc.'s Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol

Regeneron Pharmaceuticals, Inc. Announces the Lancet Published One-Year Results from the Pivotal Pulsar and Photon Trials for EYLEA HD (Aflibercept) Injection 8 Mg

Recent updates

Regeneron Pharmaceuticals, Inc. Announces Positive Pivotal Data from the Phase 1/2 LINKER-MM1 Trial of Linvoseltamab in Patients with Heavily Pre-Treated Multiple Myeloma

Regeneron Pharmaceuticals, Inc., Annual General Meeting, Jun 14, 2024

Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) completed the acquiistion of R&D pipeline from 2seventy bio, Inc. (NasdaqGS:TSVT) for $20 million.

Regeneron Pharmaceuticals, Inc Provides Update on Biologics License Application for Odronextamab

Regeneron Pharmaceuticals, Inc.'s Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol

Regeneron Pharmaceuticals, Inc. Announces the Lancet Published One-Year Results from the Pivotal Pulsar and Photon Trials for EYLEA HD (Aflibercept) Injection 8 Mg

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts Dupixent®? (Dupilumab) Sbla for Treatment of Copd with Type 2 Inflammation

Regeneron Pharmaceuticals, Inc. Announces Linvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority Review

Regeneron Pharmaceuticals, Inc. and Sanofi Announces the Ministry of Health, Labor and Welfare in Japan Grants Marketing and Manufacturing Authorization for Dupixent (Dupilumab) for the Treatment of Chronic Spontaneous Urticaria

Insider recently sold €7.1m worth of stock

Full year 2023 earnings released: EPS: US$37.05 (vs US$40.51 in FY 2022)

Regeneron Pharmaceuticals, Inc. Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Multiple Myeloma

Regeneron Pharmaceuticals, Inc. Appoints Jason Pitofsky as Controller, Expects to Occur on February 5, 2024

Regeneron Pharmaceuticals, Inc. and Sanofi Announce That U.S. Food and Drug Administration Approves Dupixent®? (Dupilumab) for the Treatment of Children Aged 1 Year and Older with Eosinophilic Esophagitis

Regeneron Pharmaceuticals, Inc. and Sanofi Announce U.S. Food and Drug Administration Updates the Label for Dupixent (Dpilumab)

Regeneron Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 02, 2024

Regeneron Pharmaceuticals, Inc. Announces New and Updated Data for Odronextamab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Pivotal Trial Showed Deep and the Potential of ctDNA to Predict Long-Term Outcomes

Regeneron Pharmaceuticals, Inc. Announces Updated Linvoseltamab Pivotal Data Demonstrated Strong Rates and Depth of Response in Patients with Heavily Pre-Treated Multiple Myeloma

Regeneron Pharmaceuticals, Inc. Announces Presentation of New and Updated Data on Multiple Combination Therapies from its Oncology Pipeline at ESMO IO Congress 2023

Regeneron Pharmaceuticals, Inc. Announces the Second Dupixent (Dupilumab) Investigational Phase 3 Chronic Obstructive Pulmonary Disease (COPD) Trial

Regeneron Pharmaceuticals, Inc. Announces the Second Dupixent (Dupilumab) Investigational Phase 3 Chronic Obstructive Pulmonary Disease (COPD) Trial

Third quarter 2023 earnings released: EPS: US$9.48 (vs US$12.31 in 3Q 2022)

Regeneron Pharmaceuticals, Inc. Announces Long-Term Outcomes and New Analyses of Pivotal Clinical Data for EYLEA®? HD (aflibercept) Injection 8mg

Regeneron Pharmaceuticals, Inc. Shares Preliminary Results Showing Gene Therapy Improves Auditory Responses in Child with Profound Genetic Hearing Loss

Regeneron Pharmaceuticals, Inc. and Sanofi Provide Update on Dupixent®? (Dupilumab) sBLA for Chronic Spontaneous Urticaria

Regeneron Pharmaceuticals, Inc. Announces Clinical Data from Innovative Oncology Portfolio in Several Difficult-to-Treat Cancers at ESMO

Regeneron Pharmaceuticals, Inc. Announces the First Presentation of Positive Two-Year Results from the Pivotal Pivotal Pulsar Trial Investigating Eylea Hd (Aflibercept) Injection 8 Mg with 12-Week Dosing Regimens

Regeneron Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Accepts Odronextamab BLA for Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma for Priority Review

Regeneron Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepted for Priority Review

Regeneron Pharmaceuticals, Inc. Announces Executive Changes

Regeneron Pharmaceuticals, Inc. Announces Executive Changes

Regeneron Pharmaceuticals, Inc. Announces Board Changes

Regeneron Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Approves EYLEA HD (Aflibercept) Injection 8 Mg

Regeneron Pharmaceuticals, Inc. Announces Two-Year PULSAR Trial Results for Aflibercept 8 mg Demonstrate Durable Vision Gains at Extended Dosing Intervals in Wet Age-Related Macular Degeneration

Second quarter 2023 earnings released: EPS: US$9.05 (vs US$7.90 in 2Q 2022)

Regeneron Pharmaceuticals, Inc. Announces the First Presentation of Positive Two-Year Results from the Pivotal PHOTON Trial Investigating Aflibercept 8 mg with 12- and 16-Week Dosing Regimens

Regeneron Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 03, 2023

FDA Issues Complete Response Letter (CRL) for Aflibercept 8 Mg Biologics License Application Solely Due to an Ongoing Review of Inspection Findings At A Third-Party Filler

Regeneron Pharmaceuticals, Inc. Provides Updated Data from Two Phase 2 Expansion Dose Cohorts Evaluating Investigational Linvoseltamab

First quarter 2023 earnings released: EPS: US$7.64 (vs US$9.12 in 1Q 2022)

Regeneron Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Approved Eylea Injection

Full year 2022 earnings released: EPS: US$40.51 (vs US$76.40 in FY 2021)

Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) announces an Equity Buyback for $3,000 million worth of its shares.

Regeneron Pharmaceuticals, Inc. and Sanofi Announce European Commission Expands the Marketing Authorization for Dupixent® (Dupilumab) in the European Union

Regeneron Pharmaceuticals, Inc. to Report Q4, 2022 Results on Feb 03, 2023

Regeneron Pharmaceuticals, Inc. Announces Libtayo (cemiplimab) Receives Approval in Japan for Advanced or Recurrent Cervical Cancer

Regeneron Pharmaceuticals, Inc. Demonstrates High and Durable Complete Response Rate Among Patients with Relapsed/Refractory Follicular Lymphoma in Pivotal Phase 2 Trial

Regeneron Pharmaceuticals, Inc. Announces Pivotal Odronextamab (Cd20xcd3) Phase 2 Data in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Debut At ASH

Regeneron ESMO IO Presentations Highlight Potential of Fianlimab and Libtayo(R) (cemiplimab) in Multiple Solid Tumor Types

Evkeeza(R) (evinacumab-dgnb) sBLA for Children with Ultra-rare Inherited Form of High Cholesterol Accepted for FDA Priority Review

Regeneron Pharmaceuticals, Inc. Announces Libtayo (cemiplimab) Approved by the European Commission as the First Immunotherapy in Second Line Recurrent or Metastatic Cervical Cancer Irrespective of PD-L1 Expression Level or Tumor Histology

Regeneron Pharmaceuticals, Inc Announces Dupixent® (Dupilumab) Recommended for EU Approval by the CHMP for the Treatment of Prurigo Nodularis

Regeneron Pharmaceuticals, Inc. Announces Libtayo in Combination with Chemotherapy Approved by the FDA as First-Line Treatment for Advanced Non-Small Cell Lung Cancer

Regeneron Pharmaceuticals, Inc. Updates Results from Two Positive Pivotal Trials Investigating Novel Aflibercept 8 Mg with 12- and 16-Week Dosing Regimens

Third quarter 2022 earnings released: EPS: US$12.31 (vs US$15.37 in 3Q 2021)

Shareholder Returns

Price Volatility

About the Company